GUTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GUTS is not a good buy right now for a beginner with long-term goals and $50,000-$100,000 to invest. The stock is trading weakly in pre-market at $0.62, the business has no recent positive news, financials show sharp deterioration in revenue and gross margin, and there is no strong proprietary buy signal. Even though one analyst is positive on the longer-term REMAIN-1 readout, the current setup is too speculative and weak for an impatient beginner investor.
GUTS is in a mixed-to-weak technical position. Pre-market price is 0.62, down 2.75%, which shows immediate selling pressure. MACD histogram is slightly positive at 0.0146 but is contracting, suggesting momentum is fading rather than strengthening. RSI_6 at 65.141 is near the upper neutral zone and does not signal a clear breakout. Moving averages are converging, which usually reflects indecision rather than a strong trend. Price is sitting above pivot 0.593 but below resistance 0.655, so upside needs a breakout that is not confirmed yet. Short-term trend estimates are modestly positive, but not strong enough to offset the weak broader picture.
["H.C. Wainwright maintains a Buy rating with an $8 price target, indicating belief in meaningful upside if future REMAIN-1 data is favorable.", "The analyst sees the upcoming Q4 REMAIN-1 pivotal readout as a potential catalyst for Revita and the company\u2019s long-term strategy.", "The stock has some statistical upside potential based on pattern analysis over the next week and month."]
["No news in the recent week, so there is no fresh event-driven catalyst supporting the stock now.", "Pre-market price is down 2.75%, showing weak immediate sentiment.", "Revenue in 2025/Q4 dropped to 0, down 100.00% YoY.", "Gross margin dropped to 0, down 100.00% YoY.", "Net income remains deeply negative at -43.7 million, and EPS also worsened.", "Hedge funds and insiders are both neutral, with no significant buying interest.", "No AI Stock Picker signal today and no recent SwingMax entry signal."]
In 2025/Q4, Fractyl Health showed very weak financial performance. Revenue fell to 0 from the prior year, gross margin also fell to 0, and EPS declined to -0.31. Net income was still deeply negative at -43.7 million, although the loss was somewhat smaller year over year. Overall, the latest quarter indicates a company with no current sales momentum and heavy ongoing losses.
Recent analyst sentiment is mixed but skewed cautiously positive on the long-term story. H.C. Wainwright kept a Buy rating and $8 target, arguing the REMAIN-1 data should be viewed in the context of the broader Revita trajectory and upcoming pivotal readout. However, the market reacted very negatively to the January six-month randomized data, with investors focused on lack of statistical significance and weight-regain kinetics. Wall Street’s bull case is based on future clinical validation and a potentially durable procedure after GLP-1 discontinuation, while the bear case is that current data quality and execution risk remain high. Overall, pros are betting on future clinical catalysts, but the current market view remains skeptical.
